• Japanese
  • Korean
  • Chinese
Cover Image

Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Abstract

Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Traumatic Brain Injury Therapeutics market. The report identifies the key trends shaping and driving the global Traumatic Brain Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Traumatic Brain Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

Scope

The report provides information on the key drivers and challenges of the Traumatic Brain Injury Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Traumatic Brain Injury Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Traumatic Brain Injury Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Traumatic Brain Injury Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Traumatic Brain Injury Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Traumatic Brain Injury Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Traumatic Brain Injury Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Traumatic Brain Injury Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Traumatic Brain Injury Therapeutics - Introduction 8

  • 2.1 Disease Overview 8
    • 2.1.1 Classification of Traumatic Brain Injury 9
    • 2.1.2 Types of Traumatic Brain Injury 11
    • 2.1.3 Effects of Traumatic Brain Injury 12
    • 2.1.4 Post-Injury Complications Associated with Traumatic Brain Injury 13
  • 2.2 Epidemiology 14
    • 2.2.1 Traumatic Brain Injury: "A Silent Epidemic" in the US 16
    • 2.2.2 The UK 17
    • 2.2.3 Spain 17
    • 2.2.4 France 17
    • 2.2.5 Italy 17
    • 2.2.6 Germany 17
    • 2.2.7 Japan 17
    • 2.2.8 Mortality 18
    • 2.2.9 Quality of Life Parameters 19
    • 2.2.10 Pharmacoeconomic Burden 19
  • 2.3 Etiology 19
  • 2.4 Pathophysiology 21
    • 2.4.1 Primary Injury 21
    • 2.4.2 Secondary Injury 22
    • 2.4.3 Inflammatory Response 23
    • 2.4.4 Repair-Regeneration 23
  • 2.5 Signs and Symptoms 23
  • 2.6 Diagnosis 24
    • 2.6.1 Initial Measures 24
    • 2.6.2 Complete Clinical Evaluation 25
  • 2.7 Treatment and Management Pattern 28
    • 2.7.1 Acute Management of Traumatic Brain Injury in Hospital 28
    • 2.7.2 Treatment of Mild Traumatic Brain Injury 33
    • 2.7.3 Treatment of Post-Traumatic Brain Injury Complications 36
    • 2.7.4 Rehabilitation 39
  • 2.8 Referral Pathway 39
  • 2.9 GlobalData Pipeline Report Guidance 41

3 Traumatic Brain Injury Therapeuctics - Market Characterization 42

  • 3.1 Overview 42
  • 3.2 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - Global 43
  • 3.3 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - Global 44
  • 3.4 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury - Global 45
  • 3.5 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - The US 46
  • 3.6 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - The US 47
  • 3.7 Traumatic Brain Injury Therapeutics Market Distribution based on Severity of Injury - The US 48
  • 3.8 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - France 49
  • 3.9 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - France 50
  • 3.10 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, France 51
  • 3.11 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - Germany 52
  • 3.12 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - Germany 53
  • 3.13 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Germany 54
  • 3.14 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - Italy 55
  • 3.15 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - Italy 56
  • 3.16 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Italy 57
  • 3.17 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - Spain 58
  • 3.18 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - Spain 59
  • 3.19 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Spain 60
  • 3.20 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - The UK 61
  • 3.21 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - The UK 62
  • 3.22 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, The UK 63
  • 3.23 Traumatic Brain Injury Therapeutics Market Size (2006-2011) - Japan 64
  • 3.24 Traumatic Brain Injury Therapeutics Market Forecast (2011-2019) - Japan 65
  • 3.25 Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Japan 66
  • 3.26 Drivers and Barriers for Traumatic Brain Injury Therapeutics Market 67
    • 3.26.1 Drivers for Traumatic Brain Injury Therapeutics Market 67
    • 3.26.2 Barriers for TBI Therapeutics Market 67
  • 3.27 Opportunity and Unmet Need Analysis 69
    • 3.27.1 Opportunity and Unmet Need in Traumatic Brain Injury Therapeutics Market 69
  • 3.28 Key Takeaway 69

4 Traumatic Brain Injury Therapeutics - Competitive Assessment 70

  • 4.1 Overview 70
  • 4.2 Strategic Competitor Assessment 70
  • 4.3 Product Profile for the Major Product in the Traumatic Brain Injury Therapeutics 70
    • 4.3.1 Mannitol 70
  • 4.4 Key Takeaway 71

5 Traumatic Brain Injury Therapeutics - Pipeline Assessment 72

  • 5.1 Overview 72
  • 5.2 Strategic Pipeline Assessment 72
  • 5.3 Traumatic Brain Injury Therapeutics Pipeline - Pipeline by Phases of Development 73
    • 5.3.1 Traumatic Brain Injury Therapeutics - Phase III Pipeline 73
    • 5.3.2 Traumatic Brain Injury Therapeutics -Phase II Pipeline 73
    • 5.3.3 Traumatic Brain Injury Therapeutics - Phase I/II Pipeline 74
    • 5.3.4 Traumatic Brain Injury Therapeutics -Phase I Pipeline 74
    • 5.3.5 Traumatic Brain Injury Therapeutics - IND Filed 74
    • 5.3.6 Traumatic Brain Injury Therapeutics - Preclinical Phase 75
    • 5.3.7 Traumatic Brain Injury Therapeutics - Discovery Pipeline 75
  • 5.4 Technology Trends Analytic Framework 76
  • 5.5 Traumatic Brain Injury Therapeutics Market -Pipeline by Mechanism of Action 78
  • 5.6 Molecule Profiling for Promising Drug under Clinical development 79
    • 5.6.1 BHR-100 79
  • 5.7 Key Takeaway 80

6 Traumatic Brain Injury Therapeutics - Clinical Trials Mapping 81

  • 6.1 Clinical Trials by Region/ Country 81
  • 6.2 Clinical Trials by Phase 82
  • 6.3 Clinical Trials by Trial Status 83
  • 6.4 Top 10 companies participating in Therapeutics Clinical Trials 84
  • 6.5 Prominent Sponsors 85

7 Traumatic Brain Injury Therapeutics - Strategic Assessment 87

  • 7.1 Key Events Impacting the Future Traumatic Brain Injury Market 87
  • 7.2 Implications for Future Traumatic Brain Injury Market Competition 88

8 Traumatic Brain Injury Therapeutics - Future Players 89

  • 8.1 Introduction 89
  • 8.2 Company Profiles 89
    • 8.2.1 BHR Pharma, LLC 89

9 Traumatic Brain Injury Therapeutics - Appendix 90

  • 9.1 Market Definitions 90
  • 9.2 Abbreviations 90
  • 9.3 Bibliography 91
  • 9.4 Research Methodology 93
    • 9.4.1 Coverage 93
    • 9.4.2 Secondary Research 94
    • 9.4.3 Primary Research 94
    • 9.4.4 Modelling and Forecasting 94
    • 9.4.5 Expert Panel Validation 97
  • 9.5 Contact Us 97
  • 9.6 Disclaimer 98

List of Tables

1.1 List of Tables

  • Table 1: Glasgow Coma Scale 9
  • Table 2: Clinical Severity (Injury Severity Score) 10
  • Table 3: Severity of Brain Injury 10
  • Table 4: Structural Damage (CT) 11
  • Table 5: Types of Traumatic Brain Injury 11
  • Table 6: Immediate Post-Injury Complications 13
  • Table 7: Long-Term Complications Associated with Traumatic Brain Injury 14
  • Table 8: Incidence Pool of Traumatic Brain Injury Patients in Seven Major Markets 14
  • Table 9: Rates of Disability in the General Population of the US 16
  • Table 10: Key Opinion Leader Insights, Mortality Rate of Traumatic Brain Injury in the US, the UK and Japan 18
  • Table 11: Symptoms of Traumatic Brain Injury 23
  • Table 12: Frequency of Mild Traumatic Brain Injury Symptoms in General Population and in Traumatic Brain Injury Patients 24
  • Table 13: Severity Assessment of Traumatic Brain Injury based on GCS 24
  • Table 14: Key Opinion Leader Insights, Diagnosis Rate of Traumatic Brain Injury in the US, the UK and Japan 27
  • Table 15: Key Opinion Leader Insights, Percentage of Traumatic Brain Injury Patients Develop Complications 29
  • Table 16: Key Opinion Leader Insights, Geographical Differences in Treatment and Management Pattern of Medical Complications of Traumatic Brain Injury, 2012 32
  • Table 17: Treatment and Management of Headache (Includes Tension and Migraine) 33
  • Table 18: Treatment and Management of Dizziness and Disequilibrium 34
  • Table 19: Treatment and Management of Fatigue and Sleep Disturbances 34
  • Table 20: Treatment and Management of Vision, Hearing, Olfactory Symptoms 34
  • Table 21: Treatment and Management of Irritability 35
  • Table 22: Treatment and Management of Appetite Changes and Nausea 35
  • Table 23: Management of Traumatic Brain Injury Sequelaes with Pharmacological Agents 37
  • Table 24: Traumatic Brain Injury Therapeutics Market, Global, Market Size, ($m), 2006-2011 43
  • Table 25: Traumatic Brain Injury Therapeutics Market, Global, Forecast ($m), 2011-2019 44
  • Table 26: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Global 45
  • Table 27: Traumatic Brain Injury Therapeutics Market, The US, Market Size, ($m), 2006-2011 46
  • Table 28: Traumatic Brain Injury Therapeutics Market, The US, Forecast ($m), 2011-2019 47
  • Table 29: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of TBI, The US 48
  • Table 30: Traumatic Brain Injury Therapeutics Market, France, Market Size, ($m), 2006-2011 49
  • Table 31: Traumatic Brain Injury Therapeutics Market, France, Forecast ($m), 2011-2019 50
  • Table 32: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, France 51
  • Table 33: Traumatic Brain Injury Therapeutics Market, Germany, Market Size, ($m), 2006-2011 52
  • Table 34: Traumatic Brain Injury Therapeutics Market, Germany, Forecast ($m), 2011-2019 53
  • Table 35: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Germany 54
  • Table 36: Traumatic Brain Injury Therapeutics Market, Italy, Market Size, ($m), 2006-2011 55
  • Table 37: Traumatic Brain Injury Therapeutics Market, Italy, Forecast ($m), 2011-2019 56
  • Table 38: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, Italy 57
  • Table 39: Traumatic Brain Injury Therapeutics Market, Spain, Market Size, ($m), 2006-2011 58
  • Table 40: Traumatic Brain Injury Therapeutics Market, Spain, Forecast ($m), 2011-2019 59
  • Table 41: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of TBI, Spain 60
  • Table 42: Traumatic Brain Injury Therapeutics Market, The UK, Market Size, ($m), 2006-2011 61
  • Table 43: Traumatic Brain Injury Therapeutics Market, The UK, Forecast ($m), 2011-2019 62
  • Table 44: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, The UK 63
  • Table 45: Traumatic Brain Injury Therapeutics Market, Japan, Market Size, ($m), 2006-2011 64
  • Table 46: Traumatic Brain Injury Therapeutics Market, Japan, Forecast ($m), 2011-2019 65
  • Table 47: Traumatic Brain Injury Therapeutics Market Distribution based upon Severity of Injury, The UK 66
  • Table 48: Traumatic Brain Injury Therapeutics - Phase III Clinical Pipeline, 2012 73
  • Table 49: Traumatic Brain Injury Therapeutics - Phase II Clinical Pipeline, 2012 73
  • Table 50: Traumatic Brain Injury Therapeutics - Phase I/II Clinical Pipeline, 2012 74
  • Table 51: Traumatic Brain Injury Therapeutics - Phase I Clinical Pipeline, 2011 74
  • Table 52: Traumatic Brain Injury Therapeutics - IND Filed, 2012 74
  • Table 53: Traumatic Brain Injury Therapeutics -Preclinical Pipeline, 2012 75
  • Table 54: Traumatic Brain Injury Therapeutics - Discovery Pipeline, 2012 75
  • Table 55: Traumatic Brain Injury Therapeutics Market, Clinical Trials by Region/ Country, 2012 81
  • Table 56: Traumatic Brain Injury Therapeutics Market, Clinical Trials by Phase, 2012 82
  • Table 57: Traumatic Brain Injury Therapeutics Market, Clinical Trials by Trial Status, 2012 83
  • Table 58: Traumatic Brain Injury Therapeutics Market, Clinical Trials by Top Companies Participating in Traumatic Brain Injury Therapeutics Clinical Trials, 2012 84
  • Table 59: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Overall Sponsors, 2012 85
  • Table 60: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Prominent Sponsors, 2012 86
  • Table 61: BHR Pharma - Central Nervous System Pipeline Products, 2011 89

List of Figures

1.2 List of Figures

  • Figure 1: Effects of Traumatic Brain Injury 12
  • Figure 2: Key Opinion Leader Insights, Incidence Trend of Traumatic Brain Injury in the US, the UK and Japan 15
  • Figure 3: Comparison of Annual Incidence of Traumatic Brain Injury with Other Diseases 16
  • Figure 4: Average Annual Rates for Traumatic Brain Injury Deaths, by Age Group and Sex- The US, 1997-2007 18
  • Figure 5: Causes of Traumatic Brain Injury 20
  • Figure 6: Processes in Traumatic Brain Injury 21
  • Figure 7: Various Pathological Findings Detected in CT Scan in Traumatic Brain Injury Patients 26
  • Figure 8: Diagnostic Approaches in Traumatic Brain Injury 27
  • Figure 9: Post-Traumatic Brain Injury Medical Complications 36
  • Figure 10: Treatment Continuum of Traumatic Brain Injury 39
  • Figure 11: Key Opinion Leader Insights, Referral Pathway of Traumatic Brain Injury in the US, the UK and Japan 40
  • Figure 12: Traumatic Brain Injury Therapeutics Market, Global, Market Size ($m), 2006-2011 43
  • Figure 13: Traumatic Brain Injury Therapeutics Market, Global, Forecast ($m), 2011-2019 44
  • Figure 14: Traumatic Brain Injury Therapeutics Market, The US, Market Size ($m), 2006-2011 46
  • Figure 15: Traumatic Brain Injury Therapeutics Market, The US, Forecast ($m), 2011-2019 47
  • Figure 16: Traumatic Brain Injury Therapeutics Market, France, Market Size ($m), 2006-2011 49
  • Figure 17: Traumatic Brain Injury Therapeutics Market, France, Forecast ($m), 2011-2019 50
  • Figure 18: Traumatic Brain Injury Therapeutics Market, Germany, Market Size ($m), 2006-2011 52
  • Figure 19: Traumatic Brain Injury Therapeutics Market, Germany, Forecast ($m), 2011-2019 53
  • Figure 20: Traumatic Brain Injury Therapeutics Market, Italy, Market Size ($m), 2006-2011 55
  • Figure 21: Traumatic Brain Injury Therapeutics Market, Italy, Forecast ($m), 2011-2019 56
  • Figure 22: Traumatic Brain Injury Therapeutics Market, Spain, Market Size ($m), 2006-2011 58
  • Figure 23: Traumatic Brain Injury Therapeutics Market, Spain, Forecast ($m), 2011-2019 59
  • Figure 24: Traumatic Brain Injury Therapeutics Market, The UK, Market Size ($m), 2006-2011 61
  • Figure 25: Traumatic Brain Injury Therapeutics Market, The UK, Forecast ($m), 2011-2019 62
  • Figure 26: Traumatic Brain Injury Therapeutics Market, Japan, Market Size ($m), 2006-2011 64
  • Figure 27: Traumatic Brain Injury Therapeutics Market, Japan, Forecast ($m), 2011-2019 65
  • Figure 28: Projected Growth in Road Traffic Fatalities, 2002-2020: A Comparison of World Bank Projections with Global Burden of Disease Projections 68
  • Figure 29: Key Opinion Leader Insights, Unmet Need in Traumatic Brain Injury Therapeutics Market 69
  • Figure 30: Traumatic Brain Injury Therapeutics Pipeline by Phase of Development, 2012 73
  • Figure 31: Technology Trends Analytic Framework of the Traumatic Brain Injury Therapeutics Pipeline, 2012 76
  • Figure 32: Technology Trends Analytic Framework of the Traumatic Brain Injury Therapeutics Pipeline- Description, 2012 77
  • Figure 33: Traumatic Brain Injury Therapeutics, Pipeline by Mechanism of Action, 2011 78
  • Figure 34: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Region/Country, 2012 81
  • Figure 35: Traumatic Brain Injury Therapeutics Market - Clinical Pipeline by Phase, 2012 82
  • Figure 36: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Trial Status, 2012 83
  • Figure 37: Traumatic Brain Injury Therapeutics Market, Clinical Trials by Top Companies Participating in Traumatic Brain Injury Therapeutics Clinical Trials, 2012 84
  • Figure 38: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Overall Sponsors, 2012 85
  • Figure 39: Traumatic Brain Injury Therapeutics Market - Clinical Trials by Prominent Sponsors, 2012 86
  • Figure 40: Traumatic Brain Injury Therapeutics Market, Drivers and Barriers, 2012 87
  • Figure 41: Implications for Future Market Competition in the Traumatic Brain Injury Therapeutics Market, 2011 88
  • Figure 42: GlobalData Market Size Estimation 95
  • Figure 43: GlobalData Market Forecasting Model 97
Show More
Pricing